A STATement on Vemurafenib-Resistant Melanoma
Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad therapeutic approa...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713534/ |